produced substantial symptomatic improvement and increased maximal oxygen uptake at 1 week. Patients were further improved after 4 weeks of WIN 47203, and maximal oxygen uptake increased from 9.0 ± 1.9 to 11.6 ± 2.5 ml/kg/min (p < 0.01 vs control). No overt clinical or laboratory manifestations of toxicity were observed. Withdrawal of WIN 47203 in two patients in whom clinical benefit was not sustained resulted in clinical and hemodynamic deterioration, which was reversed by reinstitution of the drug. Therefore, this study demonstrates the acute and sustained cardiotonic efficacy of WIN 47203 in man. If long-term administration remains well tolerated and without side effects, this drug appears to be very promising for treatment of chronic severe congestive heart failure.
PATIENTS with congestive heart failure become increasingly symptomatic as the severity of the disease progresses. In the advanced stage of the disease, patients are severely incapacitated despite optimal therapy with diuretics, digitalis and vasodilators.'-3 Amrinone, a nonglycosidic, nonadrenergic cardiotonic agent, improves ventricular performance and reduces symptoms at rest and during exertion.7 However, amrinone therapy is complicated by various side effects, e.g., thrombocytopenia, gastrointestinal intolerance, hepatotoxicity and fever.8 These side effects occur most often during the first month of therapy. WIN 47203 is a new nonglycosidic, nonadrenergic cardiotonic agent with a chemical structure analogous to that of amrinone9I
In vitro and in vivo, WIN 47203 is a more potent inotropic agent than amrinone.9 Moreover, oral WIN 47203 administered to normal volunteers for 4 weeks has not been associated with untoward effects.10 We undertook the present study to evaluate the hemodynamic and clinical responses and safety of prolonged administration of WIN 47203 to patients with severe congestive heart failure.
Methods

Subjects
Therapy with WIN 47203 was offered to 11 patients with chronic congestive heart failure who were severely incapacitated despite treatment with diuretics, digitalis and nitrates. Eight of the patients had not benefited from therapy with arteriolar vasodilators, which were therefore discontinued. The severity of the functional impairment was confirmed by a maximal oxygen uptake below 12 ml/kg/min in every patient (average 9.0 ml/kg/min, range 6-11.2 ml/kg/min). The nature, benefits and risks of the study were fully explained and all patients gave informed consent. The protocol was approved by the Committee on Clinical Investigations of the Albert Einstein College of Medicine. The average age of the patients was 60 + 2 years (range 42-70 years). Heart failure resulted from coronary artery disease in nine patients and from idiopathic cardiomyopathy in two. No patient had hypertension or a recent myocardial infarction. Nine patients were in sinus rhythm and two had atrial fibrillation. Six patients who had episodes of nonsustained ventricular tachycardia during 24-hour Holter monitoring were treated successfully with procainamide. Left ventricular ejection fraction obtained by gated radionuclide imaging averaged 24% (range 16-37%). Patients were admitted to the coronary care unit at least 48 hours before hemodynamic evaluation. A strict dietary regimen including 2 g of sodium was prescribed and nitrates were discontinued. Patients continued to receive their usual daily doses of digoxin and diuretic during the study. The average serum digoxin level at the start of therapy was 1.1 ± 0.3 ng/ml.
Hemodynamics
After 24 hours of bed rest, the patients underwent right-heart catheterization performed with a flow-directed, balloon-tipped thermodilution catheter (Edwards Laboratories). Mean pulmonary arterial, pulmonary wedge and right atrial pressures were recorded on a photographic recorder (Electronics for Medicine). Cardiac output was determined by the thermodilution technique using iced 5% dextrose in water and obtained in triplicate with less than 10% variation. Systemic arterial pressure was measured directly using an indwelling catheter inserted percutaneously into the radial artery. Derived hemodynamic variables, including cardiac index, stroke volume index and systemic vascular resistance, were calculated from standard formulas. Cardiac index was below 2.5 1/min/m2 in every patient. An electrocardiographic lead was monitored continuously throughout the study.
Exercise Capacity Assessment
Treadmill exercise was performed according to the protocol of Patterson et al. II Patients were tested at the same time of day at least 4 hours after taking their medications. Before therapy with WIN 47203, two exercise tests were performed to determine reproducibility. Measurements of mixed expired oxygen, mixed expired carbon dioxide, expired volume, expired gas temperature and barometric pressure were performed at rest and every 30 seconds throughout exercise using a metabolic measurement cart (Beckman Instruments). The patients were breathing through a mouthpiece attached to a low-resistance, nonrebreathing, three-way valve with a nose clamp. The oxygen analyzer (OM-11 Beckman Instruments) and carbon dioxide analyzer (LB-2, Beckman Instruments) were calibrated using an analyzed mixture of approximately 4% carbon dioxide and 16% oxygen in nitrogen. This calibration was made within 1 hour of the testing. Oxygen uptake (ml/kg/min) was calculated using standard formulas. 12 fig. 1) . The time course of the hemodynamic response to an oral dose of 5 mg is shown in figure 2.
The maximal increase in cardiac index occurred 60-90 minutes after oral administration. Cardiac index remained significantly elevated for 2 hours and pulmonary capillary wedge pressure significantly lowered for 3 hours. The hemodynamic response for six consecutive doses was monitored in six patients ( fig. 3) . The maximal changes in cardiac index and pulmonary capillary wedge pressure were similar after the first, third and sixth doses. Although a sustained increase in cardiac index was observed in some patients before the sixth dose, the average cardiac index before the sixth dose was not statistically different from the initial control value.
Clinical Response
Eight of the 10 patients receiving chronic therapy with WIN 47203 were substantially improved after 1 week of therapy. Their weight remained unchanged, and fatigue and dyspnea were reduced at rest and during exercise. An average increase in maximal oxygen uptake of 1.0 ml/kg/min (range 0.5-2.2 ml/kg/min) confirmed the symptomatic improvement. However, almost all of the patients noticed that the initial clinical benefits lasted 3-5 hours after oral administration; thus, their symptoms often returned before the next 10 To what extent the improvement in cardiac performance resulted from the positive inotropic action and from the direct vasodilator action of WIN 47203 cannot be stated at the present time.
Like amrinone, WIN 47203 does not increase myocardial contractility through activation of the mechanisms attributed to digitalis glycosides or to catecholamines. WIN 47203 has similarly been demonstrated to inhibit phosphodiesterase from guinea pig heart tissue.'0 Although a positive correlation has been found in the guinea pig heart between the degree of phosphodiesterase inhibition and peak inotropic response produced by WIN 47203, there appears to be a temporal dissociation between the inotropic effect and the rise in cyclic AMP. Thus, the positive inotropic effect may not be directly related to the phosphodiesterase inhibition, and the mechanism of action of WIN 47203 remains to be elucidated.
Chronic therapy with WIN 47203 decreased symptoms of heart failure and increased maximal oxygen uptake during exercise in our patients. The augmentation of maximal oxygen uptake was similar to that after amrinone.7 Since the increase in maximal oxygen uptake was observed as early as I week after the initiation of therapy, it appears likely that improved cardiac performance and oxygen delivery to exercising muscles was responsible. Subsequently, an amelioration of symptoms and increased physical activity at submaximal work loads afforded by WIN 47203 therapy may have contributed to the further increase in maximal oxygen uptake at 4 weeks. SUMMARY Thirty-five patients with varying degrees of congestive heart failure were subjected to 600 upright tilt. Eight of the patients with normal resting hemodynamics had elevated resting plasma norepinephrine levels (PNE) (p < 0.001), but their response to upright tilt was similar to that in normal subjects: All had increases in heart rate, plasma norepinephrine (from 263 ± 32 to 483 ± 78 pg/mg, p < 0.02) and plasma renin activity (from 4.8 ± 0.9 to 13.7 ± 7.6 ng/mI/hour, p < 0.05). In 27 patients with high resting pulmonary wedge pressure and low cardiac index, resting PNE was higher (668 ± 71 ng/ml), but PNE, plasma renin activity and heart rate did not increase significantly during tilt despite a fall in pulmonary capillary wedge pressure and cardiac index. In 18 of these patients, PNE rose during tilt, whereas in nine it did not change or fell; the regting hemodynamics and the hemodynamic response to tilt were not significantly different in these two groups. These data suggest that an abnormality of mechanoreceptor or baroreceptor function is common in patients with CHF. This abnormality corresponds in part to the severity of the resting hemodynamic abnormality, but among patients with severe CHF, the reflex neurohumoral abnormality may provide independent information about the severity of the disease.
UPRIGHT TILT normally induces a fall in cardiac filling and stroke volume that elicits a neurohumoral response characterized by increases in circulating norepinephrine (PNE) levels and plasma renin activity (PRA).1' This neurohumoral response is thought to play an important role in the increases in heart rate and systemic vascular resistance that maintain arterial pressure in the upright position. The stimulus for this neurohumoral response appears to reside primarily in the cardiopulmonary area through mechanoreceptors at the junctions of the vena cava and right atrium and the pulmonary veins and left atrium, and in the left ventricle. The importance of this neurohumoral response in the support of arterial pressure is reflected by evidence that pharmacologic or pathologic inhibition of this response leads to orthostatic hypotension.7-l In congestive heart failure (CHF), PNE is usually increased and PRA is frequently increased. 12-15 If these increased plasma levels are indicative of heightened activity of these neurohumoral vasoconstrictor systems, then the stimulatory response to orthostatic stress may be altered. An understanding of the circulatory and humoral response to this stress also might provide insight into the mechanism of the heightened sympathetic and renin-angiotensin activity in CHF.
In the present study, we examined the response to orthostasis in patients with symptoms of CHF and widely divergent resting hemodynamics. Responses in this group were compared with those in a group of normal subjects subjected to the same orthostatic stress.
Methods
Thirty-five patients (31 men and four women), ages 20-80 years (mean 55.1 years), who had varying degrees of CHF were studied. All patients had been limited symptomatically by dyspnea on exertion, orthopnea or exercise intolerance for at least 6 months. All had cardiomegaly, as defined by a cardiothoracic ratio exceeding 0.5 on a standard chest x-ray. Twenty-two patients were classified as having ischemic cardiomyopathy on the basis of a history of angina and myocardial infarction (angiography demonstrated significant coronary artery disease in 15 of these patients), and 13 CIRCULATION
